Global Stem Cell Treatment Market
- MAR2978648
- 176 Pages
- August 2018
- Pharmaceuticals
Augmentation in research studies aim at broadening the utility scope of associated products is anticipated to drive the market growth in recent years. These research projects have opened the possibility of implementation of several clinical applications of these cells, thereby directly influencing disease-modifying treatments.
Market Dynamics
Stem cells have tremendous promise to help us understand and treat, monitor and control a range of diseases, injuries and other health-related conditions. Their potential is evident with the use of blood stem cells to treat diseases of the blood, a therapy that has saved the lives of thousands of children with leukemia; and can be seen in the use of stem cells for tissue grafts to treat and further control diseases or injury to the bone, skin and surface of the eye. Important clinical trials involving stem cells are underway for many other conditions and researchers continue to explore new parades using stem cells in medicine.
Market Segmentation
The stem cell treatment market is segmented on the basis of type, therapeutic application, treatment, and geography.
1. On the basis of type
--> Allogeneic stem cell therapy: The segment is expected to command the largest share in the global stem cell therapy market in 2016. This large share can primarily be ascribed to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials and researches related to allogeneic stem cell therapies.
--> Autologous stem cell therapy: Here, a patient's own blood-formingstem cells are collected. He or she is then treated with high doses of chemotherapy, or a combination of chemotherapy and radiation. The high-dose treatment kills cancer cells, and additionally, also eliminates the blood-producing cells that are left in the bone marrow.
2. On the basis of therapeutic application
--> Musculoskeletal disorders
--> Wounds and injuries
--> Cardiovascular diseases
--> Surgeries
--> Gastrointestinal diseases
Regional/Geographic Analysis
North America is expected to be the largest regional segment in the global stem cell therapy market in 2016 attributing to the technological advancements, followed by Asia-Pacific and Rest of the World.
Key players
Some of the major players in the market include NuVasive, Inc. (U.S.), Holostem Terapie Avanzate S.r.l. (Italy), MEDIPOST Co. Ltd. (South Korea), Anterogen Co. Ltd. (South Korea), Pharmicell Co. Ltd. (South Korea), JCR Pharmaceuticals Co. Ltd. (Japan), RTI Surgical Inc. (U.S.), and AlloSource (U.S.), etc.
The report contains comprehensive analysis on:
--> Stem Cell Treatment Market Segments
--> Stem Cell Treatment Market Drivers, Restraints and Opportunities
--> Stem Cell Treatment Market Size & Forecast 2016 to 2022
--> Supply & Demand Value Chain
--> Stem Cell Treatment Market Current Trends
--> Competition &Major Companies
--> Technology and R&D Status
--> Porters Five Force Analysis
--> Strategic and Critical Success Factor Analysis of Key Players
Regional analysis for Stem Cell Treatment Market includes
--> North America
>> US and Canada
--> Latin America
>> Mexico, Brazil, Argentina and Rest of Latin America
--> Western Europe
>> EU5 (Germany, France, Italy, Spain, U.K.)
>> Nordic Countries (Denmark, Finland, Norway, and Sweden)
>> Benelux (Belgium, The Netherlands, and Luxembourg)
>> Rest of Western Europe
--> Eastern Europe
>> Russia
>> Poland
>> Rest of Eastern Europe
--> Asia Pacific
>> China
>> India
>> Japan
>> Australia and New Zealand
>> Rest of Asia Pacific
--> Middle East and Africa
>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
>> South Africa
>> North Africa
>> Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides in-depth market segmentation that is derived from extensive product mapping exercises, macro-economic factors and other qualitative and quantitative insights. The impact of all such factors are delivered across multiple market segments and geographies.
Report Highlights::
--> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
--> Consumer and Pricing Analysis
--> Market dynamics of the industry
--> In-depth Market Segmentation
--> Historical and Projected Market Sizing in terms of volume and value
--> Recent market trends and Impact Factors
--> R&D Status and Technology Overview
--> Extensive Industry Structure Coverage
1.1. Market Definition
1.2. Market Taxonomy
2. Research Methodology
3. Assumptions and Acronyms
4. Executive Summary
5. Historical Overview (Market Origins, Product Launch Timeline, etc.)
6. Pricing Analysis
7. Market Dynamics
7.1. Macroeconomic Factors
7.2. Drivers
7.2.1. Supply Side
7.2.2. Demand Side
7.3. Restraints
7.4. Opportunities
8. R&D Status and Technology Overview
9. Global Stem Cell Treatment Market Analysis, By Cell Source
9.1. Introduction
9.2. Market Size and Analysis, By Cell Source
9.2.1. Embryonic Stem Cells
9.2.2. Adult Stem Cells
9.2.2.1. Hematopoietic Stem Cells
9.2.2.2. Mesenchymal Stem Cells
9.2.2.3. Others
9.2.3. Induced Pluripotent Stem Cells (iPSCs)
9.3. Market Share Analysis and YoY Growth Rates, By Cell Source
10. Global Stem Cell Treatment Market Analysis, By Transplantation Type
10.1. Introduction
10.2. Market Size and Analysis, By Transplantation Type
10.2.1. Autotranplantation
10.2.2. Allotransplantation
10.2.3. Others (Syngeneic and Xenotransplantion)
10.3. Market Share Analysis and YoY Growth Rates, By Transplantation Type
11. Global Stem Cell Treatment Market Analysis, By Treatment Type
11.1. Introduction
11.2. Global Stem Cell Treatment Market Size and Analysis, By Treatment Type
11.2.1. Cancer Treatments
11.2.2. Hematologic diseases
11.2.3. Metabolic Disorders
11.2.4. Viral Diseases (HIV/HTLV/etc.)
11.2.5. Lysosomal storage disorders
11.2.6. Immunodeficiencies
11.2.7. Others
11.3. Global Stem Cell Treatment Market Size and Analysis, Potential and Developing Treatments
11.3.1. Neurological Disorders
11.3.2. Cardiovascular
11.3.3. Spinal Cord Injuries
11.3.4. Diabetes
11.3.5. Cosmetic and Dental
11.3.6. Orthopedics
11.3.7. Others
11.4. Market Share Analysis and YoY Growth Rates, By Treatment Type
12. Global Stem Cell Treatment Market Analysis, By Banking and Ancillaries
12.1. Introduction
12.2. Market Size and Analysis, By Banking and Ancillaries
12.2.1. Stem Cell Banking
12.2.2. Stem Cell Ancillaries
12.3. Market Share Analysis and YoY Growth Rates, By Banking and Ancillaries
13. Global Stem Cell Treatment Market Analysis, By Region
13.1. Introduction
13.2. Market Size and Analysis, By Region
13.2.1. North America
13.2.2. Latin America
13.2.3. Europe
13.2.4. Asia Pacific
13.2.5. Middle East & Africa (MEA)
13.3. Market Share Analysis and YoY Growth Rates, By Region
14. North America Stem Cell Treatment Market Analysis
14.1. Introduction
14.2. Prominent Trends
14.3. North America Stem Cell Treatment Market Analysis, by Country
14.3.1. U.S.
14.3.2. Canada
14.4. North America Stem Cell Treatment Market Analysis, By Cell Source
14.4.1. Embryonic Stem Cells
14.4.2. Adult Stem Cells
14.4.2.1. Hematopoietic Stem Cells
14.4.2.2. Mesenchymal Stem Cells
14.4.2.3. Others
14.4.3. Induced Pluripotent Stem Cells (iPSCs)
14.5. North America Stem Cell Treatment Market Analysis, By Transplantation Type
14.5.1. Autotranplantation
14.5.2. Allotransplantation
14.5.3. Others (Syngeneic and Xenotransplantion)
14.6. North America Stem Cell Treatment Market Analysis, By Treatment Type
14.6.1. Cancer Treatments
14.6.2. Hematologic diseases
14.6.3. Metabolic Disorders
14.6.4. Viral Diseases (HIV/HTLV/etc.)
14.6.5. Lysosomal storage disorders
14.6.6. Immunodeficiencies
14.6.7. Others
14.7. North America Stem Cell Treatment Market Analysis, By Banking and Ancillaries
14.7.1. Stem Cell Banking
14.7.2. Stem Cell Ancillaries
14.8. North America Stem Cell Treatment Market Share Analysis and YoY Growth Rates
14.8.1. By Country
14.8.2. By Cell Source
14.8.3. By Transplantation Type
14.8.4. By Treatment Type
14.8.5. By Banking and Ancillaries
15. Latin America Stem Cell Treatment Market Analysis
15.1. Introduction
15.2. Prominent Trends
15.3. Latin America Stem Cell Treatment Market Analysis, by Country
15.3.1. Mexico
15.3.2. Brazil
15.3.3. Others
15.4. Latin America Stem Cell Treatment Market Analysis, By Cell Source
15.4.1. Embryonic Stem Cells
15.4.2. Adult Stem Cells
15.4.2.1. Hematopoietic Stem Cells
15.4.2.2. Mesenchymal Stem Cells
15.4.2.3. Others
15.4.3. Induced Pluripotent Stem Cells (iPSCs)
15.5. Latin America Stem Cell Treatment Market Analysis, By Transplantation Type
15.5.1. Autotranplantation
15.5.2. Allotransplantation
15.5.3. Others (Syngeneic and Xenotransplantion)
15.6. Latin America Stem Cell Treatment Market Analysis, By Treatment Type
15.6.1. Cancer Treatments
15.6.2. Hematologic diseases
15.6.3. Metabolic Disorders
15.6.4. Viral Diseases (HIV/HTLV/etc.)
15.6.5. Lysosomal storage disorders
15.6.6. Immunodeficiencies
15.6.7. Others
15.7. Latin America Stem Cell Treatment Market Analysis, By Banking and Ancillaries
15.7.1. Stem Cell Banking
15.7.2. Stem Cell Ancillaries
15.8. Latin America Stem Cell Treatment Market Share Analysis and YoY Growth Rates
15.8.1. By Country
15.8.2. By Cell Source
15.8.3. By Transplantation Type
15.8.4. By Treatment Type
15.8.5. By Banking and Ancillaries
16. Europe Stem Cell Treatment Market Analysis
16.1. Introduction
16.2. Prominent Trends
16.3. Europe Stem Cell Treatment Market Analysis, by Country
16.3.1. Germany
16.3.2. U.K.
16.3.3. Spain
16.3.4. France
16.3.5. Italy
16.3.6. Russia
16.3.7. Others
16.4. Europe Stem Cell Treatment Market Analysis, By Cell Source
16.4.1. Embryonic Stem Cells
16.4.2. Adult Stem Cells
16.4.2.1. Hematopoietic Stem Cells
16.4.2.2. Mesenchymal Stem Cells
16.4.2.3. Others
16.4.3. Induced Pluripotent Stem Cells (iPSCs)
16.5. Europe Stem Cell Treatment Market Analysis, By Transplantation Type
16.5.1. Autotranplantation
16.5.2. Allotransplantation
16.5.3. Others (Syngeneic and Xenotransplantion)
16.6. Europe Stem Cell Treatment Market Analysis, By Treatment Type
16.6.1. Cancer Treatments
16.6.2. Hematologic diseases
16.6.3. Metabolic Disorders
16.6.4. Viral Diseases (HIV/HTLV/etc.)
16.6.5. Lysosomal storage disorders
16.6.6. Immunodeficiencies
16.6.7. Others
16.7. Europe Stem Cell Treatment Market Analysis, By Banking and Ancillaries
16.7.1. Stem Cell Banking
16.7.2. Stem Cell Ancillaries
16.8. Europe Stem Cell Treatment Market Share Analysis and YoY Growth Rates
16.8.1. By Country
16.8.2. By Cell Source
16.8.3. By Transplantation Type
16.8.4. By Treatment Type
16.8.5. By Banking and Ancillaries
17. Asia Pacific Stem Cell Treatment Market Analysis
17.1. Introduction
17.2. Prominent Trends
17.3. Asia Pacific Stem Cell Treatment Market Analysis, by Country
17.3.1. India
17.3.2. China
17.3.3. Australia & New Zealand
17.3.4. Japan
17.3.5. Others
17.4. Asia Pacific Stem Cell Treatment Market Analysis, By Cell Source
17.4.1. Embryonic Stem Cells
17.4.2. Adult Stem Cells
17.4.2.1. Hematopoietic Stem Cells
17.4.2.2. Mesenchymal Stem Cells
17.4.2.3. Others
17.4.3. Induced Pluripotent Stem Cells (iPSCs)
17.5. Asia Pacific Stem Cell Treatment Market Analysis, By Transplantation Type
17.5.1. Autotranplantation
17.5.2. Allotransplantation
17.5.3. Others (Syngeneic and Xenotransplantion)
17.6. Asia Pacific Stem Cell Treatment Market Analysis, By Treatment Type
17.6.1. Cancer Treatments
17.6.2. Hematologic diseases
17.6.3. Metabolic Disorders
17.6.4. Viral Diseases (HIV/HTLV/etc.)
17.6.5. Lysosomal storage disorders
17.6.6. Immunodeficiencies
17.6.7. Others
17.7. Asia Pacific Stem Cell Treatment Market Analysis, By Banking and Ancillaries
17.7.1. Stem Cell Banking
17.7.2. Stem Cell Ancillaries
17.8. Asia Pacific Stem Cell Treatment Market Share Analysis and YoY Growth Rates
17.8.1. By Country
17.8.2. By Cell Source
17.8.3. By Transplantation Type
17.8.4. By Treatment Type
17.8.5. By Banking and Ancillaries
18. Middle East and Africa (MEA) Stem Cell Treatment Market Analysis
18.1. Introduction
18.2. Prominent Trends
18.3. Middle East and Africa Stem Cell Treatment Market Analysis, by Country
18.3.1. GCC countries
18.3.2. South Africa
18.3.3. North Africa
18.3.4. Rest of Middle East and Africa
18.4. MEA Stem Cell Treatment Market Analysis, By Cell Source
18.4.1. Embryonic Stem Cells
18.4.2. Adult Stem Cells
18.4.2.1. Hematopoietic Stem Cells
18.4.2.2. Mesenchymal Stem Cells
18.4.2.3. Others
18.4.3. Induced Pluripotent Stem Cells (iPSCs)
18.5. MEA Stem Cell Treatment Market Analysis, By Transplantation Type
18.5.1. Autotranplantation
18.5.2. Allotransplantation
18.5.3. Others (Syngeneic and Xenotransplantion)
18.6. MEA Stem Cell Treatment Market Analysis, By Treatment Type
18.6.1. Cancer Treatments
18.6.2. Hematologic diseases
18.6.3. Metabolic Disorders
18.6.4. Viral Diseases (HIV/HTLV/etc.)
18.6.5. Lysosomal storage disorders
18.6.6. Immunodeficiencies
18.6.7. Others
18.7. MEA Stem Cell Treatment Market Analysis, By Banking and Ancillaries
18.7.1. Stem Cell Banking
18.7.2. Stem Cell Ancillaries
18.8. MEA Stem Cell Treatment Market Share Analysis and YoY Growth Rates
18.8.1. By Country
18.8.2. By Cell Source
18.8.3. By Transplantation Type
18.8.4. By Treatment Type
18.8.5. By Banking and Ancillaries
19. Industry Structure
19.1. Porters Five Forces Analysis
19.1.1. Bargaining Power of Suppliers
19.1.2. Bargaining Power of Buyers
19.1.3. Threat of New Entrants
19.1.4. Threat of Substitute Treatment Type
19.1.5. Internal Rivalry
19.2. Supply Chain Analysis and Profitability Margins
19.3. Market Share Analysis
19.4. Strategic Analysis
19.4.1. Competitive Strategies
19.4.2. Mergers & Acquisitions Activity
19.4.3. Co-operative Agreements
19.5. Critical Success Factor (CSF) Analysis (Technology & Manufacturing, Design & Features, Brand
Reputation, Distribution Network, Marketing)
19.6. Company Profiles (Overview, Product/Service Details, Geographic Scope, Financials, Strategic
Intent & Approach, Core Competencies & Competitive Advantage and Key developments)
19.6.1. Osiris Therapeutics, Inc.
19.6.2. Pluristem Therapeutics Inc.
19.6.3. Orthocell Ltd.
19.6.4. NuVasive, Inc. (U.S.)
19.6.5. Holostem Terapie Avanzate S.r.l. (Italy)
19.6.6. MEDIPOST Co. Ltd. (South Korea)
19.6.7. Anterogen Co. Ltd. (South Korea)
19.6.8. Pharmicell Co. Ltd. (South Korea)
19.6.9. JCR Pharmaceuticals Co. Ltd. (Japan)
19.6.10. RTI Surgical Inc. (U.S.)
19.6.11. AlloSource (U.S.)
19.6.12. Others
19.7. Big Pharma Companies
19.8. Startups and Advanced Research Companies
20. Prognosis for the Future
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
